Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
1 Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Italy
2 Oncologia, Ospedale Sacro Cuore-Don Calabria, Negrar, (VR), Italy
3 Struttura Complessa di Oncologia Falck, Ospedale Niguarda Ca’ Granda, Milan, Italy
4 UO Oncologia, Azienda Ospedaliera Sant’Anna, Como, Italy
5 U.O.C. di Oncologia dell’Ospedale Civile Maggiore, Azienda Ospedaliera-Universitaria di Verona, Verona, Italy
6 Oncologia Medica, Ospedale di Bolzano, Bolzano, Italy
7 Oncologia, Azienda Ospedaliera di Alessandria, Alessandria, Italy
8 SC Oncologia, Azienda Ospedaliero-Universitaria “Maggiore della Carità”, Novara, Italy
9 Oncologia Medica, Ospedale Campo di Marte, Lucca, Italy
10 UO Oncologia Medica, Ospedale S.S. Trinità, Sora (FR), Sassari, Italy
11 Oncologia Medica, Università degli Studi Messina, Messina, Italy
12 Medical & Scientific Department, Sanofi-Aventis, Milan, Italy
13 Division of Medical Oncology, Ospedale S. Maria della Misericordia, Azienda Ospedaliera Perugia, via Dottori 1, Perugia, 06122, Italy
BMC Cancer 2012, 12:158 doi:10.1186/1471-2407-12-158Published: 30 April 2012
The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of 90%. However, some retrospective studies reported a 10-y RFS of 81%–86% and suggested benefit from adjuvant systemic therapy.
To evaluate the variables that determined the choice of adjuvant chemotherapy and the type of chemotherapy delivered in pT1a-pT1b BC, we analysed the small tumours enrolled in the NEMESI study.
Out of 1,894 patients with pathological stage I-II BC enrolled in NEMESI, 402 (21.2%) were pT1a-pT1b. Adjuvant chemotherapy was delivered in 127/402 (31.59%). Younger age, grading G3, high proliferative index, ER-negative and HER2-positive status were significantly associated with the decision to administer adjuvant chemotherapy. An anthracycline without taxane regimen was administered in 59.1% of patients, anthracycline with taxane in 24.4%, a CMF-like regimen in 14.2% and taxane in 2.4%. Adjuvant chemotherapy was administered in 88.4% triple-negative and 73.46% HER2-positive pT1a-pT1b BC. Adjuvant trastuzumab was delivered in 30/49 HER2-positive BC (61.2%).
Adjuvant chemotherapy was delivered in 31.59% T1a-pT1b BC treated at 63 Italian oncological centres from January 2008 to June 2008. The choice to deliver chemotherapy was based on biological prognostic factors. Anthracycline-based chemotherapy was administered in 83.5% patients.